Dr. Ryan Gordon Holstead, MD

Dr. Holstead practices at Umass Memorial Medical Center in Mendon, Massachusetts.

Dr. Holstead's NPI, 1952753873, was assigned on July 2, 2016. Dr. Holstead graduated from State University of NY Upstate Medical University in 2016. Dr. Holstead holds Massachusetts license 1014566.

Dr. Holstead's primary practice is Umass Memorial Medical Center, at 55 North Ave, Mendon, MA 01756 in Worcester County. The practice phone is (508) 334-1000.

Dr. Holstead's primary practice is Umass Memorial Medical Center in Mendon, Massachusetts. Dr. Holstead is also affiliated with UMass Memorial Medical Center - University Campus. The medical group on file is UMass Memorial Medical Group. Dmand AI also links Dr. Holstead to 2 more hospitals, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Holstead practices, 3 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Holstead's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Holstead is licensed in Massachusetts.

CMS data shows 532 Medicare services from Dr. Holstead across 7 procedure codes in 2024, for 193 Medicare patients. Medicare paid $51,309 for them.

CMS counts 193 Medicare patients who saw Dr. Holstead in 2024. The largest group is 65 to 74, with 88 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 40% are also on Medicaid. Their average risk score is 2.39, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Holstead's median patient age at 71, with 40% women.

In 2024, Dr. Holstead wrote 634 Medicare Part D claims for 131 patients. 87% of them were for generic drugs. CMS names the drug for 441 of them, across 18 drugs with 11 or more claims each, at $325,590 in total drug cost. In 2023, CMS named 665 claims across 32 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Holstead for performance year 2024, reported through an alternative payment model (APM). Dr. Holstead accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Holstead as offering telehealth.

Dmand AI links 14 papers to Dr. Holstead, published from 2010 to 2022. 2020 was the busiest year, with 5. The most frequent topics are Immune Checkpoint Inhibitors, Melanoma and Immunotherapy. Dr. Holstead has published most often in Immunotherapy. Dr. Holstead's most frequent co-authors are Sidra Khalid, MD, Maged Mofied Ghaly, MD and Dev Prakash Kamdar, MD.

CMS Open Payments shows 41 general payments to Dr. Holstead from 23 drug and device companies from 2021 to 2024. Food and beverage make up the largest share, 99% of the total. Bristol-Myers Squibb Company paid the most, $188.

Dr. Holstead graduated from State University of NY Upstate Medical University in 2016.